<DOC>
	<DOCNO>NCT01975831</DOCNO>
	<brief_summary>This multicenter , open-label , study standard 3+3 dose-escalation phase , follow expansion phase subject solid tumor</brief_summary>
	<brief_title>A Phase 1 Study Evaluate MEDI4736 Combination With Tremelimumab</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<criteria>1 . Histologically cytologicallyconfirmed ovarian cancer , colorectal cancer , nontriple negative breast cancer , renal cell carcinoma cervical cancer , least one lesion measurable irRC previously irradiate . 2 . Failed respond relapse follow standard treatment , decline eligible standard treatment . 3 . ECOG performance status 02 . 4 . Anticipated lifespan great 6 month . 5 . At time day 1 study , subject brain metastasis must asymptomatic least 4 week : least 8 week without tumor progression whole brain radiotherapy least 4 week since craniotomy resection stereotactic radiosurgery least 3 week without new brain metastasis evidence MRI/CT 6 . Adequate organ marrow function , define : Hemoglobin ≥ 9 g/dL Absolute Neutrophil Count ≥ 1500/mm3 Platelet count ≥ 100,000/mm3 Total bilirubin within normal range unless associate hepatobiliary metastasis Gilbert syndrome , total bilirubin ≤ 2 x ULN Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN unless associate hepatic metastasis , ALT AST ≤ 5 x ULN Creatinine ≤ 2.0 mg/dL 7 . Have inform treatment option . 8 . Age ≥18 year . 9 . Able willing give valid write informed consent . 10 . Able willing give valid write consent archival tumor sample 11 . Able willing give valid write consent biopsy sample ( subject expansion phase ) . 1 . Prior exposure tremelimumab MEDI4736 antiCTLA4 , antiPD1 , antiPDL1 antibody 2 . History severe allergic reaction unknown allergen component study drug . 3 . Active prior autoimmune disease except autoimmune thyroiditis vitiligo . 4 . Any prior Grade ≥ 3 immunerelated adverse event ( irAE ) prior corticosteroidrefractory irAE . 5 . Known active chronic viral hepatitis history type hepatitis within last 6 month . 6 . History sarcoidosis syndrome . 7 . Active history inflammatory bowel disease ( colitis , Crohn 's ) , diverticulitis , irritable bowel disease , celiac disease , serious , chronic , gastrointestinal condition associate diarrhea . Active history systemic lupus erythematosus Wegener 's granulomatosis . 8 . Metastatic disease central nervous system therapeutic option , include radiotherapy , may available . 9 . Known immunodeficiency active HIV . 10 . Other active serious illness ( e.g. , serious infection require antibiotic ) . 11 . If subject previously receive investigational treatment , last dose investigational treatment administer within 4 week Day 1 study adverse event ( ) attributable investigational treatment resolve Grade 1 better . 12 . Major surgical procedure ( defined investigator ) within 30 day prior Day 1 still recover prior surgery . 13 . Mental impairment may compromise ability give informed consent comply requirement study . 14 . Lack availability immunological clinical followup assessment . 15 . Women breast feed pregnant evidence positive serum pregnancy test . 16 . Females childbearing potential sexually active nonsterilized male partner must use 2 method effective contraception screening , must agree continue use precaution 6 month final dose investigational product ; cessation birth control point discuss responsible physician . Periodic abstinence , rhythm method , withdrawal method acceptable method birth control . Females childbearing potential define surgically sterile ( i.e. , bilateral tubal ligation , bilateral oophorectomy , complete hysterectomy ) postmenopausal ( defined 12 month menses without alternative medical cause ) . Nonsterilized male sexually active female partner childbearing potential must use 2 acceptable method effective contraception Day 1 6 month receipt final dose investigational product . 17 . Any condition , clinical judgment treat physician , likely prevent subject comply aspect protocol may put subject unacceptable risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Non Triple Negative Breast Cancer</keyword>
</DOC>